Founded QR Pharma to develop better therapeutics for neurodegenerative diseases. Was partner and director of Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; GM of Bachem Bioscience and Head Molecular Biology Mallinckrodt. Did a postdoc at Caltech and one at Roche Institute of Immunology. PhD in biochemistry is from The Rockefeller Univ.

Over 30 years experience in the Biotechnology, focused on matters relating to regulatory affairs, strategic planning and execution of development programs, including manufacturing, preclinical and clinical projects, writing and review of respective documentation for submission to FDA, and regulatory application review management in a wide range of therapeutic areas.

Ph.D. in Biological Chemistry with over seventeen years of experience managing product development and regulatory submissions in the pharmaceutical industry. Experience includes writing and reviewing protocols; selecting and monitoring preclinical, analytical and clinical sites; writing and reviewing reports; preparing summaries, Investigators’ Brochures, INDs, NDAs, and worldwide regulatory submissions; and managing professional staff.

Senior level executive accomplished in successful early and commercial stage venture development, venture capital, private equity and bank financings, line operations, project and international finance. CFO of venture capital-backed
development-stage pharmaceutical company and CEO of venture capital-backed agribusiness company.

Dr. Grundman is providing leadership for the clinical strategy and development at QR. Dr. Grundman currently is a Professor of Neurosciences at the University of California San Diego (UCSD) and previously served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy Research & Development, LLC and as Vice President of Clinical Development at Elan Pharmaceuticals.

Mr. Hoffman is a Partner of Riverstone, where he is principally responsible for investments in power and renewable energy for Riverstone’s funds. Mr. Hoffman is co-head of Riverstone's Renewable Energy Funds I and II, with equity capital commitments of approximately $5 billion.